Zepbound vs Wegovy

Zepbound vs Wegovy: the short answer

In trial averages Zepbound produced more weight loss, but Wegovy has a longer track record and broader insurance familiarity. The cheaper option for you usually comes down to which manufacturer's self-pay or savings program your dose and coverage qualify for.

Zepbound is tirzepatide (GIP/GLP-1 receptor agonist) and Wegovy is semaglutide (GLP-1 receptor agonist), so they are different molecules with different average results.

On cost alone, Zepbound tends to be the cheaper option — its lowest realistic monthly price starts around $0, versus about $0 for Wegovy.

How each medication works

Zepbound is a GIP/GLP-1 receptor agonist taken as a once-weekly subcutaneous injection. It is FDA-approved for Chronic weight management and Obstructive sleep apnea in obesity.

Wegovy is a GLP-1 receptor agonist taken as a once-weekly subcutaneous injection. It is FDA-approved for Chronic weight management and Cardiovascular risk reduction.

The mechanisms differ: tirzepatide acts on the GLP-1 pathway, while semaglutide works through the GLP-1 pathway as well.

Effectiveness: average weight loss

In clinical data, Zepbound was associated with roughly 21% average body-weight reduction over about 72 weeks (SURMOUNT-1 trial (tirzepatide, highest dose)).

Wegovy was associated with roughly 15% over about 68 weeks (STEP 1 trial (semaglutide 2.4 mg)).

Head-to-head averages favor Zepbound, but individual results vary widely with dose, diet, activity, and how long you stay on treatment. These figures are trial averages, not guarantees.

Cost comparison

Zepbound: full cash price is around $1,086/mo. With a manufacturer savings program it can drop to about $349/mo, and telehealth routes run roughly $349–$599/mo.

Wegovy: full cash price is around $1,349/mo. With savings it can drop to about $499/mo, and telehealth routes run roughly $299–$599/mo.

Use the cost calculator to plug in your insurance status and state — the cheapest route often depends on coverage far more than on which drug you pick.

Side effects and safety

The most common side effects overlap heavily: Zepbound lists nausea, diarrhea, vomiting, and constipation; Wegovy lists nausea, diarrhea, vomiting, and constipation. Most are gastrointestinal and tend to ease as the dose is titrated up slowly.

Both carry serious warnings, including a boxed warning about the risk of thyroid C-cell tumors, and should not be used by people with a personal or family history of medullary thyroid carcinoma or MEN 2. Only a licensed clinician can decide whether either is appropriate for you.

Insurance and how to get each

Zepbound: Growing commercial coverage for obesity; not covered by traditional Medicare for weight loss. Prior authorization common.

Wegovy: Covered by some commercial plans for obesity; Medicare added limited coverage tied to cardiovascular risk. Coverage varies widely by plan.

If coverage is denied, most people compare a manufacturer savings program against a telehealth subscription or a compounded alternative where it is still legally available.

Which should you choose?

Choose Zepbound if maximizing average weight loss is the priority and you can access it affordably. Choose Wegovy if it is easier to get covered or cheaper for your situation.

Whichever you lean toward, run your specifics through the calculator and take our 60-second quiz to see which telehealth provider can actually get it to you for the least.